Information Provided By: 
Fly News Breaks for March 12, 2019
MYGN
Mar 12, 2019 | 07:25 EDT
Needham analyst Stephen Unger raised his price target on Myriad Genetics to $41 and kept his Strong Buy rating after meeting with its management last week to discuss the company's short and long term issues and opportunities. The analyst says the discussions have left him "incrementally bullish" on the stock given its "potential for meaningful revenues from expanded commercial payor coverage of GeneSight and Foresight". Unger is also positive on the company's "promising incremental opportunity in melanoma testing through myPath Melanoma".
News For MYGN From the Last 2 Days
There are no results for your query MYGN
